Hepatitis C drug development at a crossroads-Reference-Cited by-同舟云学术

Hepatitis C drug development at a crossroads

Published:2009-08-05 Issue:4 Volume:50 Page:997-999
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Nelson David R.

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.23208/fullpdf

Reference14 articles.

1. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection;McHutchison;N Engl J Med,2009

2. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection;Hézode;N Engl J Med,2009

3. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron/ribavirin in treatment naïve subjects with genotype-1 chronic hepatitis C;Kwo;J Hepatol,2009

4. Manns M Muir A Adda N Jacobsen I Afdhal N Heathcote J Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa2a/b and ribavirin therapy: SVR results of the PROVE3 study 2009

5. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients;Kieffer;HEPATOLOGY,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Nonoxidative Passerini Pathway to α-Ketoamides;Synlett;2015-10-15

2. Diagnostic Accuracy of Point-of-Care Tests for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis;PLOS ONE;2015-03-27

3. Spontaneous Weight Change during Chronic Hepatitis C Treatment: Association with Virologic Response Rates;International Journal of Medical Sciences;2013

4. Patientsʼ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection;The Patient: Patient-Centered Outcomes Research;2012-12

5. Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection;The Patient: Patient-Centered Outcomes Research;2012-12